Samsung Medison, a global medical equipment company affiliated with Samsung Electronics, has finalized an agreement to acquire 100% of the shares of France-based Sonio, a fetal ultrasound AI software company.
Established in 2020, Sonio focuses on improving women and children’s health globally through medical advancements. The company specializes in developing IT solutions and AI assistant features for obstetrics and gynecology ultrasound, aiding medical professionals in evaluating and documenting ultrasound exams.
One of Sonio’s key offerings is Sonio Detect, an FDA 510(k) cleared AI assistant designed to ensure higher image quality in real time. This technology aims to enhance clinical accuracy and improve the quality of care provided during ultrasound examinations.
Post-acquisition, Sonio will maintain its independence as a company headquartered in France. Its products and services will remain compatible with ultrasound devices from various manufacturers, ensuring seamless integration in healthcare settings.
The collaboration between Samsung Medison and Sonio aims to drive innovation in prenatal care. By leveraging Samsung Medison’s advanced ultrasound systems and Sonio’s AI expertise, the companies intend to introduce breakthrough AI-enhanced workflows to the market, revolutionizing the prenatal ultrasound exam experience.
“We have great respect and admiration for what the Sonio team has built in the area of maternal care. Through the acquisition of Sonio, Samsung Medison will continue to deliver upon our promise to improve the quality of people’s lives with technology,” said Yong Kwan Kim, Samsung Medison CEO. “Collaboration with Sonio will bring together best-in-class ultrasound AI technology and reporting capabilities to bring a paradigm shift in the prenatal ultrasound exam.”
“Samsung Medison’s established global ultrasound business combined with Sonio’s advanced AI creates an exciting growth opportunity for both sides,” said Cécile Brosset, Sonio CEO. “We have found in Samsung Medison an amazing, trusting partner to pursue and accelerate our roadmap and mission. In addition to close collaboration with Samsung Medison, as an independent company, Sonio will continue to advance medical reporting technology and diagnostic software globally, including for underserved areas in healthcare.”
The acquisition is subject to regulatory approvals, including those from the French Ministry of the Economy and Finance.
